Oncotype DX® Prostate Cancer Assay

The Oncotype DX® Prostate Cancer Assay is a multigene genomic test that - based on the analysis of selected genes in tumor tissue sample from biopsy using RT-PCR method - predicts the aggressiveness of the disease. This test measures the expression of 17 genes across multiple key biological pathways in prostate cancer and thanks to that it can help predict the aggressiveness of the disease and provide more precise and individualized risk assessment beyond traditional clinical pathologic factors such as Gleason score or PSA.

The Oncotype DX® Prostate Cancer Assay 17- gene panel (12 cancer related and 5 reference genes) is highly predictive of adverse pathology. It includes 4 biological pathways and the following algorithm leads to the final Genomic Prostate Score (GPS).

For further information about Oncotype DX® Prostate Cancer Assay contact us by phone +420 603 413 160 or by e-mail at info@xeneo.cz.

You can also find more information about Genomic Health, Inc. at www.genomichealth.com.

Please visit www.oncotypedx.com for more detailed information about Oncotype DX® in English.

 

 

Oncotype DX® Prostate Cancer Assay is not currently reimbursed from public health insurance resources. The test can be paid by patients from their own resources. Please do not hesitate to contact us by phone or email (contacts) for more detailed information about the price.

 
 

References

  1. Klein, Cooperberget al, Euro Urol (2014)